<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639089</url>
  </required_header>
  <id_info>
    <org_study_id>MD166/2020</org_study_id>
    <nct_id>NCT04639089</nct_id>
  </id_info>
  <brief_title>The Effect of Platelet Rich Pasma on Strenal Healing Post Median Strenotomy in Patients Undergoing Open Heart Surgery</brief_title>
  <official_title>The Effect of Platelet Rich Pasma on Strenal Healing Post Median Strenotomy in Patients Undergoing Open Heart Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Hamdy Singab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Platelet-rich plasma (PRP) is an autologous concentration of human platelets in a small&#xD;
      volume of plasma.&#xD;
&#xD;
      Because it is an autogenous preparation, PRP is inherently safe and therefore free from&#xD;
      concerns over transmissible diseases such as HIV and hepatitis.&#xD;
&#xD;
      Its power of regeneration already proved by orthopedics and dentists in their trials to&#xD;
      regenerate cartilages .We will use it to know its ability to enhance healing of sternum in&#xD;
      vulnerable patients to sternal dehiscence after open heart surgery .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. INTRODUCTION Successful healing of the sternum after open heart surgery is a complicated&#xD;
           phenomenon because of the natural body ability often fails to efficiently repaired of&#xD;
           the sternum in patients after open cardiac surgery (Everts 2006). Recent evidence based&#xD;
           data suggested new modalities to increase the quality and accerelate sternal healing in&#xD;
           high risk patients after open heart surgery vulnerable for early sternal dehiscence (Liu&#xD;
           2002) . PRP considers as an attractive alternative option in that manner. Marx and&#xD;
           associates demonstrated the positive influence of PRP on bone regeneration and healing&#xD;
           since 1998 (Marx 1998 ) . Autologous PRP carries minimal risk of infectious diseases&#xD;
           transmission, immunologic reactions, and rejection. PRP with concentrations 4 to 5 folds&#xD;
           of the normal average platelet (1,100,000 platelets/Î¼l ) proved to have a remarkable&#xD;
           increase in bone mineral density and regeneration . the market for PRP grows from $45&#xD;
           million in 2009 to more than $120 million by 2016 (Dawood 2018 ). Multiple factors&#xD;
           affect the PRP efficacy in sternal bone healing and regeneration process. Platelet&#xD;
           preparation before surgical application is an area of concern with PRP. For this issue,&#xD;
           an appropriate anticoagulant must be used to prevent the early spontaneous activation of&#xD;
           the platelets (Kassolis 2000 ). Several anticoagulants have been employed for PRP&#xD;
           preparation including heparin, citrate, acid-citrate-dextrose solution A or&#xD;
           anticoagulant citrate dextrose-A ,citrate-phos phate-dextrose&#xD;
           ,citrate-theophylline-adenosine- dipyrimadole and ethylene diamine tetra- acetic acid&#xD;
           moreover, several manual or automated systems have been designed for preparing PRP&#xD;
           including clinical laboratory methods and kits (Carlson 2002). PRP produced by single-&#xD;
           or double-step centrifugation technology via platelet-pheresis (autologous selective&#xD;
           filtration )and the cell separators,However, these methods are rarely used nowadays, due&#xD;
           to several factors including high cost, large volume of peripheral blood should be&#xD;
           harvested from the patients, and potentially damage to the platelet (Dhurat 2014) .&#xD;
           Commercially available PRP kits and devices differ in ease of use, one or two step&#xD;
           centrifugation protocols, centrifugation speed, final PRP volume, platelet count and&#xD;
           activation, platelet and growth factor concentrations, and final RBCs' and WBCs'&#xD;
           count.Nevertheless, the cost of the commercial kits for PRP processing is still a&#xD;
           challenge (Trebinjac 2020) .&#xD;
&#xD;
        2. AIM/ OBJECTIVES :&#xD;
&#xD;
           To study the Effect of platlet rich plasma on sternal healing post median sternotomy in&#xD;
           Patients undergoing open heart surgery&#xD;
&#xD;
        3. METHODOLOGY:&#xD;
&#xD;
             -  Type of Study: prospective clinical trial propensity matched comparative study&#xD;
&#xD;
             -  Study Setting: Patients refered to our Cardiothoracic department, Faculty of&#xD;
                medicine, Ain Shams University and ain shams specialized hospital to perform open&#xD;
                heart surgery who fulfill our inclusion charateria.&#xD;
&#xD;
             -  Study Period: It will be performed between march 2020 and january2022&#xD;
&#xD;
             -  Study Population:&#xD;
&#xD;
                - Inclusion Criteria: Patients with one of which&#xD;
&#xD;
                  1. patients will under go open heart surgery with BMI &gt;30 or&#xD;
&#xD;
                  2. diabetic patients&#xD;
&#xD;
                  3. patients with history of chest wall radiotherapy exposure or&#xD;
&#xD;
                  4. bilateral internal mammary artery harvesting .&#xD;
&#xD;
                  5. age &gt; 70 years old -Exclusion Criteria:&#xD;
&#xD;
                  1. patient with history of open heart surgery&#xD;
&#xD;
                  2. patients with preoperative HB level &lt;11&#xD;
&#xD;
                  3. All emergency and urgency cardiothoracic surgery&#xD;
&#xD;
             -  Sampling Method: prospective clinical trials propensity matched comparative study.&#xD;
&#xD;
             -  Sample Size: 50 patients&#xD;
&#xD;
             -  Ethical Considerations: All the patients will sign an informed consent for&#xD;
                operation and for being involved in the research and follow up process .&#xD;
&#xD;
             -  Study Tools: platlets rich plasma&#xD;
&#xD;
             -  Preparation technique : ultra centrifuge technique&#xD;
&#xD;
             -  Study Procedures:&#xD;
&#xD;
      Patient data will be collected preoperatively and intraoperatively and these risk factors&#xD;
      will be studied Patients will be distributed to two equal groups. Demographic data : Age -&#xD;
      gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA&#xD;
&#xD;
      Intraoperative :&#xD;
&#xD;
      We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of&#xD;
      them before sternal closure.&#xD;
&#xD;
      post-operative The patients will be followed till being discharged from hospital and after&#xD;
      the first 3 months after surgery sternal stability and absence of dehiscence will be primary&#xD;
      out come measure&#xD;
&#xD;
      Secondary end point :&#xD;
&#xD;
      Severe form of sternal deheiscence After 3months: stability of sternum will be assessed By CT&#xD;
      chest with 3D bone reconstruction and the value of bone density as aconfirmatory test&#xD;
&#xD;
        -  Statistical Analysis:using the arithmetic mean, standard deviation using hypothesis&#xD;
           student's &quot;t&quot; tests for quantitative data analysis, while qualitative data (ordinal,&#xD;
           categorical) will be analyzed using The chi-square test (x2) (Fisher's Exact Test). For&#xD;
           all statistical comparisons, a P value of &lt;0.05 will be considered significant and a P&#xD;
           value of &lt;0.01 will be considered highly significant.&#xD;
&#xD;
        -  Statistical Package:Data will be statistically analyzed using statistical package of&#xD;
           social science (SPSS)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2020</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA&#xD;
Intraoperative :&#xD;
We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.&#xD;
post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery sternal stability and absence of dehiscence will be primary out come measure&#xD;
Secondary end point :&#xD;
Severe form of sternal deheiscence After 3months: stability of sternum will be assessed By CT chest with 3D bone reconstruction and the value of bone density as aconfirmatory test</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sternal stability and absence of dehiscence</measure>
    <time_frame>after the first 3 months of surgery</time_frame>
    <description>Radiographic strenal healing score information was collected from 50 patients during clinical follow-up determined by CT chest 3D axial slices analysis at five locations ( manubrium, top of aortic arch, main pulmonary artery , aortic root and aortopulmonary window) using 5 - points quantitative scale 0:minimal healing&#xD;
no signs of healing&#xD;
mild healing&#xD;
moderate healing&#xD;
complete healing</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Cardiac Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>We will apply 10cm saline on the sternal edge before sternal closure</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>We will apply 10cm saline on the sternal edge before sternal closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>platlet rich plasma on sternal healing post median sternotomy</intervention_name>
    <description>Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA&#xD;
Intraoperative :&#xD;
We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.&#xD;
post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery</description>
    <arm_group_label>We will apply 10cm plasma contain 1 million platlets on the sternal edge before sternal closure</arm_group_label>
    <arm_group_label>We will apply 10cm saline on the sternal edge before sternal closure</arm_group_label>
    <other_name>PRP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with one of which&#xD;
&#xD;
               1. patients will under go open heart surgery with BMI &gt;30 or&#xD;
&#xD;
               2. diabetic patients&#xD;
&#xD;
               3. patients with history of chest wall radiotherapy exposure or&#xD;
&#xD;
               4. bilateral internal mammary artery harvesting .&#xD;
&#xD;
               5. age &gt; 70 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient with history of open heart surgery 2- patients with preoperative HB level &lt;11&#xD;
             3-All emergency and urgency cardiothoracic surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hamdy singab, PHD</last_name>
    <role>Study Director</role>
    <affiliation>faculty of medicine,ain shams unversity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>hamdy singab, PHD</last_name>
    <phone>+201001008859</phone>
    <phone_ext>11</phone_ext>
    <email>hamdi_singab@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>hamdy ahmed, PHD</last_name>
    <phone>0020226014465</phone>
    <email>drhamdy-ahmed@med.asu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamdy Singab</name>
      <address>
        <city>Cairo</city>
        <zip>11517</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hamdy singab</last_name>
      <phone>01001008859</phone>
      <email>hamdi_singab@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Carlson NE, Roach RB Jr. Platelet-rich plasma: clinical applications in dentistry. J Am Dent Assoc. 2002 Oct;133(10):1383-6.</citation>
    <PMID>12403541</PMID>
  </results_reference>
  <results_reference>
    <citation>Dhurat R, Sukesh M. Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. J Cutan Aesthet Surg. 2014 Oct-Dec;7(4):189-97. doi: 10.4103/0974-2077.150734. Review.</citation>
    <PMID>25722595</PMID>
  </results_reference>
  <results_reference>
    <citation>Kassolis JD, Rosen PS, Reynolds MA. Alveolar ridge and sinus augmentation utilizing platelet-rich plasma in combination with freeze-dried bone allograft: case series. J Periodontol. 2000 Oct;71(10):1654-61.</citation>
    <PMID>11063400</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Y, KalÃ©n A, Risto O, WahlstrÃ¶m O. Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. Wound Repair Regen. 2002 Sep-Oct;10(5):336-40.</citation>
    <PMID>12406171</PMID>
  </results_reference>
  <results_reference>
    <citation>Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: Growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jun;85(6):638-46.</citation>
    <PMID>9638695</PMID>
  </results_reference>
  <results_reference>
    <citation>Dawood AS, Salem HA. Current clinical applications of platelet-rich plasma in various gynecological disorders: An appraisal of theory and practice. Clin Exp Reprod Med. 2018 Jun;45(2):67-74. doi: 10.5653/cerm.2018.45.2.67. Epub 2018 Jun 29. Review.</citation>
    <PMID>29984206</PMID>
  </results_reference>
  <results_reference>
    <citation>Everts PA, Knape JT, Weibrich G, SchÃ¶nberger JP, Hoffmann J, Overdevest EP, Box HA, van Zundert A. Platelet-rich plasma and platelet gel: a review. J Extra Corpor Technol. 2006 Jun;38(2):174-87. Review.</citation>
    <PMID>16921694</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Dr. Hamdy Singab</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cardiac Surgical Procedures</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>planning to make IPD available to other researchers</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>data will be available after 3 YEARS and for 2 years.</ipd_time_frame>
    <ipd_access_criteria>IPD sharing access criertia including clinical researcher cardiac surgeons postgraduate investigator</ipd_access_criteria>
    <ipd_url>http://www.ctaegypt.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

